Skip to main content

Haegarda Side Effects

Generic name: C1 esterase inhibitor (human)

Medically reviewed by Philip Thornton, DipPharm. Last updated on Aug 11, 2023.

Note: This document contains side effect information about C1 esterase inhibitor (human). Some dosage forms listed on this page may not apply to the brand name Haegarda.

Applies to C1 esterase inhibitor (human): intravenous powder for solution. Other dosage forms:

Serious side effects of Haegarda

Along with its needed effects, C1 esterase inhibitor (human) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking C1 esterase inhibitor (human):

Less common

Incidence not known

Other side effects of Haegarda

Some side effects of C1 esterase inhibitor (human) may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to C1 esterase inhibitor (human): intravenous kit, intravenous powder for injection, subcutaneous powder for injection.

Respiratory

Respiratory side effects have included sinusitis, bronchitis, upper respiratory tract infection, and viral upper respiratory tract infection.[Ref]

Nervous system

Nervous system side effects have included headache.[Ref]

Musculoskeletal

Musculoskeletal side effects have included limb injury, back pain, and pain in extremity.[Ref]

Dermatologic

Dermatologic side effects have included pruritus.[Ref]

Cardiovascular

Cardiovascular side effects have included postmarketing reports of thrombotic events including deep vein thrombosis, myocardial infarction, and transient ischemic attack.[Ref]

Frequently asked questions

References

1. Product Information. Cinryze (C1 esterase inhibitor, human). ViroPharma Incorporated. 2022.

2. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy. 2012;32:902-9.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.